Allogene Therapeutics Reports Strong ALPHA3 Trial Data
South San Francisco, California | April 13, 2026 Allogene Therapeutics has announced encouraging interim results from its pivotal Phase...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
South San Francisco, California | April 13, 2026 Allogene Therapeutics has announced encouraging interim results from its pivotal Phase...
South San Francisco, California | April 10, 2026 Allogene Therapeutics has announced that it will present the interim futility...
